Literature DB >> 20209732

Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs.

Philippe De Wals1, Nicole Boulianne, Elodie Sévin, Manale Ouakki, Geneviève Deceuninck, Maryse Guay.   

Abstract

BACKGROUND: In Quebec, the pneumococcal conjugate vaccine was available on the private market as early as 2001 and has been included in the publicly funded immunization program since December 2004.
OBJECTIVES: To compare the advantages and limitations of two different sources for assessing vaccination coverage in the target population of children and to evaluate the impact of the public health program on uptake rates.
METHODS: Data from a province-wide survey of a random sample of parents and from the Quebec City Immunization Registry were used to compute vaccination rates over time in different population groups.
RESULTS: Data from the immunization survey and the regional registry were congruent regarding trends. Immunization rates were overestimated, more in the registry than in the survey. During the 2001-2004 period, uptake rates were low, and many children received fewer than the recommended number of doses. As soon as free vaccination was granted, uptake increased markedly and close to 90% of children received the recommended three doses, the level required for inducing herd effects. Delay in the administration of the third booster dose was observed.
CONCLUSIONS: Free vaccination is a major determinant of vaccine uptake and should remain a fundamental principle of the Canadian health system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20209732

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  6 in total

1.  Hospitalizations for lower respiratory tract infections in children in relation to the sequential use of three pneumococcal vaccines in Quebec.

Authors:  Zhou Zhou; Rodica Gilca; Geneviève Deceuninck; François Boucher; Philippe De Wals
Journal:  Can J Public Health       Date:  2020-06-11

Review 2.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

3.  Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in Saskatchewan.

Authors:  Ngoc-Hang Khuc; Ben Tan; Rosalie Tuchscherer; Nigel Sb Rawson; Philippe De Wals
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience.

Authors:  Pierre Alex Crisinel; Isabelle Chevalier; Fabien Rallu; Bruce Tapiero; Valérie Lamarre; Roseline Thibault; Philippe Ovetchkine
Journal:  Eur J Pediatr       Date:  2010-05-22       Impact factor: 3.183

5.  Hospitalisation for lower respiratory tract infection in children in the province of Quebec, Canada, before and during the pneumococcal conjugate vaccine era.

Authors:  G Anderson; G Deceuninck; Z Zhou; F D Boucher; Y Bonnier Viger; R Gilca; P De Wals
Journal:  Epidemiol Infect       Date:  2017-08-14       Impact factor: 4.434

Review 6.  A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States.

Authors:  John M McLaughlin; Eric A Utt; Nina M Hill; Verna L Welch; Edward Power; Gregg C Sylvester
Journal:  Hum Vaccin Immunother       Date:  2015-09-16       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.